Keywords: novartis, vacc, beats, menactra, ph, iii, trials
Novartis vacc beats Menactra in Ph III trials
Article | 12 May 2008
Swiss drug major Novartis reports its candidate Menveo (MenACWY-CRM), indicated to treat four strains of meningitis, performed better in Phase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
